Search

Displaying results 3491 - 3500 of 4539 in total
  1. Drug

    5-deoxyflavanone

    go.drugbank.com/drugs/DB03601
    Experimental

    These are compounds containing a flavan-3-one moiety, whose structure is characterized by a 2-phenyl-3,4-dihydro-2H-1-benzopyran bearing a ketone at the carbon C3.

  2. Drug

    SB-269970

    go.drugbank.com/drugs/DB13988
    Experimental

    SB-269970 is an experimental drug developed by GlaxoSmithKline.

  3. Drug

    Irampanel

    go.drugbank.com/drugs/DB21123
    Investigational

    Irampanel is under investigation in clinical trial NCT02222961 (Single Increasing Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Male Volunteers).

  4. Drug

    Aftobetin

    go.drugbank.com/drugs/DB20425
    Investigational

    Aftobetin is under investigation in clinical trial NCT02928211 (Aftobetin-HCl and Fluorescence Detection Measured by Sapphire II to Determine the Number and Timing of Administrations).

  5. Drug

    Nitisinone

    go.drugbank.com/drugs/DB00348
    Approved

    Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1 and Alkaptonuria. It is sold under the brand names Orfadin and Harliku.

  6. Drug

    Tiaprofenic acid

    go.drugbank.com/drugs/DB01600
    Approved

    Tiaprofenic acid is a non-steroidal anti-inflammatory drug employed in the treatment of pain, particularly arthritis pain. It belongs to the arylpropionic acid (profen) group of nonsteroidal anti-inflammatory drugs (NSAIDs).

  7. Drug

    RGX-181

    go.drugbank.com/drugs/DB17942
    Experimental

    Developed by REGENXBIO, it is being investigated for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease.[L47072]

  8. Drug

    IC41

    go.drugbank.com/drugs/DB05776
    Investigational

    It is being devloped by Intercell AG for the treatment of hepatitis C.

  9. Drug

    rhIGFBP-3

    go.drugbank.com/drugs/DB05897
    Investigational

    It is developed by Insmed and is currently under phase I of the clinical trial.

  10. Drug

    alpha-Hydroxy glycineamide

    go.drugbank.com/drugs/DB06568
    Experimental

    Alpha-hydroxy glycineamide (αHGA) is the active antiviral metabolite of tri-peptide glycyl-prolyl-glycine-amide (GPG-NH2). αHGA inhibits the replication of HIV-1 in vitro by interfering with the capsid